跳至主要内容
临床试验/NCT07142798
NCT07142798Enrolling By Invitation不适用

Efficacy of Bismuth/Amoxicillin/Potassium-competitive Acid Blocker Triple Therapy for the Treatment of Helicobacter Pylori Infection in Taiwan

Kaohsiung Medical University1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年9月26日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
200
试验地点
1
主要终点
Eradicaton rate of Helicobacter pylori

研究概览

简要总结

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects infected with Helicobacter pylori.

排除标准

  • Those who are allergic to the drugs used in this research.
  • Those who have had stomach surgery.
  • Those with severe liver cirrhosis or uremia or malignant tumors.
  • Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.

研究组 & 干预措施

Helicbpacyer pylori infection

Experimental

Helicbpacyer pylori infection

干预措施: Bismuth amoxilillin potassium (Drug)

结局指标

主要结局

Eradicaton rate of Helicobacter pylori

时间窗: 6 weeks after finishing study drugs

13CUBT

次要结局

  • evaluate side effect(2days after taking medicine)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

DENG-CHYANG WU

Professor

Kaohsiung Medical University

研究点 (1)

Loading locations...

相似试验